Anne Whitaker who joined Sanofi three years ago to run its North America pharmaceutical operations and help the drug maker push into potentially lucrative markets such as diabetes is leaving next month according to an internal memo Her departure comes at a difficult time for Sanofi which has been struggling to develop a diabetes unit that Chris Viehbacher the chief executive created five years ago as a linchpin of his longterm corporate growth strategy